Until recently, clinical depression treatments have fallen into just two categories: psychotherapy and antidepressant medications. But this year, the U.S. Food and Drug Administration cleared the first app-based treatment for major depressive disorder, which just became available for use this summer. The app, called Rejoyn, is cleared as a supplement to currently approved therapies and works by using specifically designed tasks on a smartphone app to rewire neural signals.